The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study
Abstract
OBJECTIVE: To assess procedural safety and glycemic indices at 6 months in a first-in-human study of duodenal mucosal resurfacing (DMR), a novel, minimally invasive, upper endoscopic procedure involving hydrothermal ablation of the duodenal mucosa, in patients with type 2 diabetes and HbA1c ≥7.5% (58 mmol/mol) on one or more oral antidiabetic agents. RESEARCH DESIGN AND METHODS: Using novel balloon catheters, DMR was conducted on varying lengths of duodenum in anesthetized patients at a single medical center. RESULTS: A total of 39 patients with type 2 diabetes (screening HbA1c 9.5% [80 mmol/mol]; BMI 31 kg/m2) were treated and included in the interim efficacy analysis: 28 had a long duodenal segment ablated (LS; ∼9.3 cm treated) and 11 had a short segment ablated (SS; ∼3.4 cm treated). Overall, DMR was well tolerated with minimal gastrointestinal symptoms postprocedure. Three patients experienced duodenal stenosis treated successfully by balloon dilation. HbA1c was reduced by 1.2% at 6 months in the full cohort (P < 0.001). More potent glycemic effects were observed among the LS cohort, who experienced a 2.5% reduction in mean HbA1c at 3 months postprocedure vs. 1.2% in the SS group (P < 0.05) and a 1.4% reduction at 6 months vs. 0.7% in the SS group (P = 0.3). This occurred despite net medication reductions in the LS cohort between 0 and 6 months. Among LS patients with a screening HbA1c of 7.5–10% (58–86 mmol/mol) and on stable antidiabetic medications postprocedure, HbA1c was reduced by 1.8% at 6 months (P < 0.01). CONCLUSIONS: Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability. Long-term safety, efficacy, and durability and possible mechanisms of action require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The intragastric balloon and transpyloric shuttle trials included some persons with T2D, but numbers were inadequate to assess safety and efficacy in those with T2D.787–789”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“Some endoscopic and orally delivered devices have been approved by the FDA for treatment of obesity, including hydrogel capsules,786 intragastric balloon systems,787–788 a transpyloric shuttle that blocks gastric emptying,789 and gastric aspiration therapy that evacuates partial gastric contents following meals via a variation of a percutaneous endoscopic gastrostomy tube.790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [787]
In the citing paper
“While weight loss following DMR is modest (~2.5 kg at six months), significant metabolic benefits have been reported.”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
In the citing paper
“Improvements in glycemic control, including a 1.2% reduction in HbA1c at six months, have been observed, particularly following long-segment ablation [92].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [92]
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Despite a wide choice of pharmacological interventions, many patients do not achieve adequate control of hyperglycemia (1).”
BackgroundRubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Self-citationRubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
Self-citationRubino, F., & Marescaux, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000102989.54824.fc · Cited by 617
Self-citationHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396 · cited 1×
“Duodenal biopsy from humans with diabetes also shows hypertrophy, thickening, and an overgrowth of entero-endocrine cell types (22).”
BackgroundLaferrère, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R. D., Wenner, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002043 · Cited by 384
Jacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Jørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Jacobsen, S. H., Serup, A. K., Albers, P. H., Hansen, D. L., Worm, D., Naver, L., Kristiansen, V. B., et al. (2014) · Diabetes · doi:10.2337/db13-1307 · Cited by 254
Breen, D. M., Rasmussen, B. A., Kokorovic, A., Wang, R., Cheung, G. W. C., & Lam, T. K. T. (2012) · Nature Medicine · doi:10.1038/nm.2745 · Cited by 209 · cited 1×
“This suggests a potential effect on hepatic glucose production, possibly through an insulin-sensitizing mechanism, in line with previous observations in duodenal-jejunal bypass (17) and Roux-en-Y gastric bypass surgery (18–20).”
Result
Cited by
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.025 · Cited by 608
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah-Pollack, R., Seger, J., et al. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0406 · Cited by 510
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Mechanick, J. I., Apovian, C., Brethauer, S., Timothy Garvey, W., Joffe, A. M., Kim, J., Kushner, R. F., Lindquist, R., Pessah‐Pollack, R., Seger, J., et al. (2020) · Obesity · doi:10.1002/oby.22719 · Cited by 389
van Baar, A. C. G., Holleman, F., Crenier, L., Haidry, R., Magee, C., Hopkins, D., Rodriguez Grunert, L., Galvao Neto, M., Vignolo, P., Hayee, B., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318349 · Cited by 201
Self-citationEndoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies
Sullivan, S., Edmundowicz, S. A., & Thompson, C. C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.044 · Cited by 167
Self-citationLong term outcomes of metabolic/bariatric surgery in adults
Courcoulas, A. P., Daigle, C. R., & Arterburn, D. E. (2023) · BMJ · doi:10.1136/bmj-2022-071027 · Cited by 164
Bariatric Surgery in the Treatment of Type 2 Diabetes
Affinati, A. H., Esfandiari, N. H., Oral, E. A., & Kraftson, A. T. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1269-4 · Cited by 157
Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323608 · Cited by 120
Self-citationEndoscopic Bariatric and Metabolic Therapies: Surgical Analogues and Mechanisms of Action
Jirapinyo, P., & Thompson, C. C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.021 · Cited by 120
“Three patients experienced duodenal stenosis and were treated successfully with balloon dilation.(72) Currently, a multicenter study is being conducted in Europe and a US pivotal trial is planned.”
BackgroundSelf-citationMetabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review
Buchwald, H., & Buchwald, J. N. (2019) · Diabetes Care · doi:10.2337/dc17-2654 · Cited by 123
“A recent interesting proposal has been endoscopic hydrothermal duodenal mucosa ablation with secondary mucosal regeneration (80,81).”
BackgroundMonteiro, M. P., & Batterham, R. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.053 · Cited by 118
Clinical Practice Update: Expert Review on Endoscopic Bariatric Therapies
Dayyeh, B. K. A., Edmundowicz, S. A., & Thompson, C. C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.035 · Cited by 100
Self-citationGastrointestinal synthetic epithelial linings
Li, J., Wang, T., Kirtane, A. R., Shi, Y., Jones, A., Moussa, Z., Lopes, A., Collins, J., Tamang, S. M., Hess, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0441 · Cited by 70
“To modulate nutrient absorption in patients with these disorders, treatments such as gastric bypass surgery, intestinal sleeve placement, intestinal mucosal resurfacing, surgical adhesives, and GI electrical stimulation have been applied(5, 6, 8, 37, 38).”
BackgroundHaidry, R. J., van Baar, A. C., Galvao Neto, M. P., Rajagopalan, H., Caplan, J., Levin, P. S., Bergman, J. J., Rodriguez, L., Deviere, J., & Thompson, C. C. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.03.024 · Cited by 66
“After successful testing of DMR safety in a large animal model, the FIH single-arm, open-label clinical study to evaluate the safety and efficacy of the DMR procedure was initiated at a single center in Santiago, Chile (CCO Clinical Center for Diabetes, Obesity, and Reflux).(12) The FIH study enrolled 57 patients who…”
BackgroundMethodSelf-citationvan Baar, A. C. G., Beuers, U., Wong, K., Haidry, R., Costamagna, G., Hafedi, A., Deviere, J., Ghosh, S. S., Lopez-Talavera, J. C., Rodriguez, L., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.006 · Cited by 55
Self-citationMetabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis
de Oliveira, G. H. P., de Moura, D. T. H., Funari, M. P., McCarty, T. R., Ribeiro, I. B., Bernardo, W. M., Sagae, V. M. T., de Freitas, J. R., de Souza, G. M. V., & de Moura, E. G. H. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05170-3 · Cited by 54
The Duodenum harbors a Broad Untapped Therapeutic Potential
van Baar, A. C. G., Nieuwdorp, M., Holleman, F., Soeters, M. R., Groen, A. K., & Bergman, J. J. G. H. M. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.010 · Cited by 55
Altered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
Smith, E. P., Polanco, G., Yaqub, A., & Salehi, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.014 · Cited by 54
van Baar, A. C. G., Meiring, S., Smeele, P., Vriend, T., Holleman, F., Barlag, M., Mostafavi, N. S., Tijssen, J. G. P., Soeters, M. R., Nieuwdorp, M., et al. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.12.021 · Cited by 50
Recent Trends in Endoscopic Bariatric Therapies
Choi, H. S., & Chun, H. J. (2017) · Clinical Endoscopy · doi:10.5946/ce.2017.007 · Cited by 51
“reduction with tolerable safety in patients with diabetes mellitus.(36)”
Salomone, F., Sharaiha, R. Z., & Boškoski, I. (2020) · Liver International · doi:10.1111/liv.14441 · Cited by 48
Recent Clinical Results of Endoscopic Bariatric Therapies as an Obesity Intervention
Bazerbachi, F., Vargas, E. J., & Dayyeh, B. K. A. (2017) · Clinical Endoscopy · doi:10.5946/ce.2017.013 · Cited by 50
“Mucosal remodeling may hypothetically reset the diseased duodenal enteroendocrine cells, thus restoring signaling, which can improve diabetes control through an incretin effect, with minimal transient decrease in body weight.(54) With the self-assembling magnets, a dual-path enteral bypass is created between the proxi…”
BackgroundHydrothermal Duodenal Mucosal Resurfacing
Cherrington, A. D., Rajagopalan, H., MAGGS, D. G., & Deviere, J. M. E. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.002 · Cited by 47
“Six-month safety and efficacy data from a single-arm, open-label, nonrandomized, first-in-human (FIH) study of Revita DMR has recently been published.(60) At the time of the report the study, performed at a single site in South America, had enrolled 44 patients with type 2 diabetes who were poorly controlled and were…”
BackgroundSelf-citationDiabetes and the Small Intestine
Gotfried, J., Priest, S., & Schey, R. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0155-x · Cited by 50
van Baar, A. C. G., Deviere, J. M. E., Hopkins, D., Crenier, L., Holleman, F., Neto, M. G., Becerra, P., Vignolo, P., Grunert, L. R., Mingrone, G., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109194 · Cited by 45
Self-citationGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“A more recently developed method, duodenal mucosal resurfacing (213), in which duodenal mucosa is ablated by a hydrothermal device, has been shown to produce euglycemia and modest weight loss and to maintain weight loss (214, 215).”
Moffett, R. C., Docherty, N. G., & le Roux, C. W. (2020) · Appetite · doi:10.1016/j.appet.2020.104807 · Cited by 45
A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going
Mauro, A., Lusetti, F., Scalvini, D., Bardone, M., Grazia, F. D., Mazza, S., Pozzi, L., Ravetta, V., Rovedatti, L., Sgarlata, C., et al. (2023) · Medicina · doi:10.3390/medicina59030636 · Cited by 44
“The 2 cm balloon catheter is designed to isolate the mucosa from the deeper layers of the duodenum by the injection of saline solution and then hydrothermally ablate the mucosa between the Ampulla of Vater and the Treitz ligament [65].”
BackgroundMethodEndoscopic intragastric balloon: a gimmick or a viable option for obesity?
Claudia Gollisch, K. S., & Raddatz, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.67 · Cited by 37
Medical devices for the treatment of obesity
Lee, P. C., & Dixon, J. B. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.80 · Cited by 38
Murad, A. J., COHEN, R. V., de Godoy, E. P., Scheibe, C. L., Campelo, G. P., RAMOS, A. C., de Lima, R. C., PINTO, L. E. V., Coelho, D., Costa, H. B. D. F., et al. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2933-x · Cited by 38
“Several other mechanisms have been proposed that may help explaining some weightindependent antidiabetic effects, as intestinal reprogramming and adaptation [11], gut hormones [12], bile acids [13], microbiota [14], and proximal bowel exclusion [15].”
BackgroundThe current state of bariatric endoscopy
McCarty, T. R., & Thompson, C. C. (2020) · Digestive Endoscopy · doi:10.1111/den.13698 · Cited by 34
Self-citationUEG Week 2018 Poster Presentations
Pittet, V., Aslan, N., Fournier, N., Decollogny, A., Schoepfer, A., Seibold, F., & Rodondi, P. Y. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618792819 · Cited by 32
Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
Hashem, A. M., Khalouf, A., & Acosta, A. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731704 · Cited by 32
Endoscopic Treatments for Obesity
Pajot, G. J., Calderón, G., & Acosta, A. J. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0158-7 · Cited by 32
Medical Devices for Obesity Treatment
Vargas, E. J., Rizk, M., Bazerbachi, F., & Dayyeh, B. K. A. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.013 · Cited by 30
“3% with greater improvements seen in the greater than 9 cm cohort compared with the less than 6-cm cohort.(49) Duodenal stenosis developed in 3 patients who were treated successfully with balloon dilation.”
BackgroundHaluzík, M., Kratochvílová, H., Haluzíková, D., & Mráz, M. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0438 · Cited by 32
Endoluminal weight loss and metabolic therapies: current and future techniques
Hill, C., Khashab, M. A., Kalloo, A. N., & Kumbhari, V. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13441 · Cited by 27
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes
Hadefi, A., Huberty, V., Lemmers, A., Arvanitakis, M., Maggs, D., Costamagna, G., & Devière, J. (2018) · Digestive Diseases · doi:10.1159/000487078 · Cited by 26
Devices and Endoscopic Bariatric Therapies for Obesity
Saunders, K. H., Igel, L. I., Saumoy, M., Sharaiha, R. Z., & Aronne, L. J. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0307-x · Cited by 26
Endoscopic Treatment of Obesity and Nutritional Aspects of Bariatric Endoscopy
Král, J., Machytka, E., Horká, V., Selucká, J., Doleček, F., Špičák, J., Kovarova, V., Haluzík, M., & Bužga, M. (2021) · Nutrients · doi:10.3390/nu13124268 · Cited by 27
Endoscopic bariatrics: current therapies and future directions
Reja, D., Zhang, C., & Sarkar, A. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.03.09 · Cited by 24
“Long and short ablations were performed at 9 cm or 3 cm in the duodenum (72), at 3 months A1C improved by 2.”
BackgroundEndoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
Hadefi, A., Verset, L., Pezzullo, M., Rosewick, N., Degré, D., Gustot, T., Moreno, C., Deviere, J. M. E., & Trépo, E. (2021) · Endoscopy International Open · doi:10.1055/a-1550-7668 · Cited by 23
Kumbhari, V., Lehmann, S., Schlichting, N. S., Heinrich, M., Kullnick, Y., Retschlag, U., Enderle, M. D., Dietrich, A., Khashab, M. A., Kalloo, A. N., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2018.02.022 · Cited by 23
Meiring, S., Meessen, E. C. E., van Baar, A. C. G., Holleman, F., Nieuwdorp, M., Damink, S. W. M. O., Schaap, F. G., Vaz, F. M., Groen, A. K., Soeters, M. R., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00337.2021 · Cited by 23
de Moura, E. G. H., Neto, A. M. D. P., Tsakmaki, A., Aiello, V. D., Bewick, G. A., & Brunaldi, V. (2019) · Endoscopy International Open · doi:10.1055/a-0862-0263 · Cited by 20
“Preclinical and clinical effectiveness and safety of DMR were previously reported [10, 11].”
BackgroundInfluentialBariatric and Metabolic Endoscopy: A New Paradigm
Telese, A., Sehgal, V., Magee, C. G., Naik, S., Alqahtani, S. A., Lovat, L. B., & Haidry, R. J. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000364 · Cited by 20
Meiring, S., van Baar, A. C. G., Sørensen, N., Holleman, F., Soeters, M. R., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.856661 · Cited by 20
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes
Hoyt, J. A., Cozzi, E., D’Alessio, D. A., Thompson, C. C., & Aroda, V. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15533 · Cited by 21
“38,39 Haidry et al. 39 attribute the stenosis cases to insufficient submucosal lift.”
BackgroundMethodInfluentialSelf-citationEndoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes
Sullivan, S. A. (2017) · Diabetes Spectrum · doi:10.2337/ds017-0046 · Cited by 19
From the Knife to the Endoscope—a History of Bariatric Surgery
Wiggins, T., Majid, M., & Agrawal, S. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00386-x · Cited by 26
van Baar, A. C. G., Haidry, R. J., Grunert, L. R., Galvao, M. P. N., Bisschops, R., Hayee, B., Costamagna, G., Deviere, J. M. E., & Bergman, J. J. G. H. M. (2020) · Endoscopy International Open · doi:10.1055/a-1244-2283 · Cited by 19
“Prior to this multicenter study, three patients from the first-in-human study developed a duodenal stenosis within 6 weeks after the procedure [12].”
BackgroundMethodLiang, Y., Yu, B., Wang, Y., Qiao, Z., Cao, T., & Zhang, P. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.02.010 · Cited by 19
Bariatric and metabolic therapies targeting the small intestine
McCarty, T. R., & Thompson, C. C. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.008 · Cited by 19
Self-citationWhat Bariatric Surgery Can Teach Us About Endoluminal Treatment of Obesity and Metabolic Disorders
Kaplan, L. M. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2017.01.004 · Cited by 17
Self-citationASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management
ASGE EndoVators Task Force, Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., & Mergener, K. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5934-x · Cited by 17
Self-citationMetabolic endoscopy: Today’s science—tomorrow’s treatment
Hadefi, A., Arvanitakis, M., Huberty, V., & Deviere, J. M. E. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620926837 · Cited by 16
Bariatric and metabolic endoscopy: impact on obesity and related comorbidities
Mehta, A., & Sharaiha, R. Z. (2021) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/26317745211019156 · Cited by 16
Endobariatric procedures for obesity: clinical indications and available options
Goyal, H., Kopel, J. J., Perisetti, A., Mann, R., Ali, A. B., Tharian, B., Saligram, S., & Inamdar, S. (2021) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/2631774520984627 · Cited by 17
Casella-Mariolo, J. R., Castagneto‐Gissey, L., Angelini, G., Zoli, A., Marini, P., Bornstein, S. R., Pournaras, D. J., Rubino, F., le Roux, C. W., Mingrone, G., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.069 · Cited by 16
Self-citationTasabehji, D., Saleh, S., & Mokadem, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124012 · Cited by 14
Endoscopic Approaches to Obesity Management
Dolan, R. D., & Schulman, A. R. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-125832 · Cited by 18
Advances in endobariatrics: past, present, and future
Shenoy, A., & Schulman, A. R. (2022) · Gastroenterology report · doi:10.1093/gastro/goad043 · Cited by 15
Garvey, W. T. (2016) · Diabetes Care · doi:10.2337/dc16-1611 · Cited by 14
“The authors stated that DMR had “an acceptable safety and tolerability profile” (1).”
BackgroundMethodInfluentialUpdated panel report: best practices for the surgical treatment of obesity
Telem, D. A., Jones, D. B., Schauer, P. R., Brethauer, S. A., Rosenthal, R. J., Provost, D. A., & Jones, S. B. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6160-x · Cited by 14
Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity
Ghusn, W., Calderón, G., Dayyeh, B. K. A., & Acosta, A. J. (2024) · Clinical Endoscopy · doi:10.5946/ce.2024.005 · Cited by 15
van Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Various Novel and Emerging Technologies in Endoscopic Bariatric and Metabolic Treatments
Na, H. K., de Moura, D. T. H., & The Study Group for Endoscopic Bariatric and Metabolic Therapies of the Korean Society of Gastrointestinal Endoscopy (2021) · Clinical Endoscopy · doi:10.5946/ce.2021.021 · Cited by 12
“The first-in-human study of DMR included 39 patients with type 2 DM and a BMI of 24–40 kg/m(2).(35) In this study, patients were grouped according to the length of circumferential ablation: the long duodenal segment ablation group (≥9 cm ablation; n=28) and the short segment ablation group (<6 cm ablation; n=11).”
van Baar, A. C. G., Meiring, S., Holleman, F., Hopkins, D., Mingrone, G., Deviere, J. M. E., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2021) · Gut · doi:10.1136/gutjnl-2020-323931 · Cited by 13
Self-citationKaur, V., Dimitriadis, G. K., Pérez‐Pevida, B., Bansi, D., Jayasena, C. N., Bate, D., Houghton, R., Fielding, B. A., Balfoussia, D., Webber, L. J., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154908 · Cited by 12
Duodenal Mucosa: A New Target for the Treatment of Type 2 Diabetes
Nie, L., Yan, Q., Zhang, S., Cao, Y., & Zhou, X. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.177 · Cited by 12
Musso, G., Pinach, S., Saba, F., Michieli, F. D., Cassader, M., & Gambino, R. (2024) · Med · doi:10.1016/j.medj.2024.03.014 · Cited by 13
Endoscopic techniques for weight loss and treating metabolic syndrome
Brunaldi, V., & Neto, M. G. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000561 · Cited by 12
Overview of bariatric and metabolic endoscopy interventions
Tawadros, A., Makar, M., Kahaleh, M., & Sarkar, A. (2020) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/2631774520935239 · Cited by 14
Miras, A. D., Kamocka, A., Tan, T., Pérez‐Pevida, B., Chahal, H., Moorthy, K., Purkayastha, S., Patel, A. G., Umpleby, A. M., Frost, G. S., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08030 · Cited by 14
Self-citationEffects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Metabolic Endoscopy: Development and Perspectives
Raddatz, D. (2019) · Digestion · doi:10.1159/000494428 · Cited by 11
Procedures and devices for bariatric and metabolic endoscopy
Orlandini, B., Gallo, C., Boškoski, I., Bove, V., & Costamagna, G. (2020) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/2631774520925647 · Cited by 12
Castagneto‐Gissey, L., Casella-Mariolo, J., & Mingrone, G. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_565 · Cited by 13
Self-citationLin, C., Yeong, T. J. J., Lim, W. H., Ng, C. H., Yau, C. E., Chin, Y. H., Muthiah, M. D., Loh, P. H., Foo, R., Mok, S. F., et al. (2022) · Obesity · doi:10.1002/oby.23453 · Cited by 12
“Although its efficacy and safety in the short term are promising (60,62), more highquality trials are needed to explore the longer-term efficacy of endoscopic interventions in T2DM.”
BackgroundLim, W. H., Lin, S. Y., Ng, C. H., Tan, D. J. H., Xiao, J., Yong, J. N., Tay, P. W. L., Syn, N. L. X., Chin, Y. H., Chan, K. E., et al. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-520 · Cited by 11
Lee, S., & Na, K. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119977 · Cited by 10
Miras, A. D., & le Roux, C. W. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.028 · Cited by 9
“…some of the components of gastric bypass surgery, i.e., the bypass of the proximal small bowel using the duodenal-jejunal bypass liner or the duodenal mucosa resurfacing, we havemanaged to achieve very reasonable reduction in weight and/or improvements in glycemia (Rajagopalan et al., 2016).”
MethodThe evolution and current state of bariatric endoscopy in Western countries
Matteo, M. V., Bove, V., Pontecorvi, V., Gualtieri, L., Carlino, G., Spada, C., & Boškoski, I. (2024) · Clinical Endoscopy · doi:10.5946/ce.2023.253 · Cited by 10
Wolfe, M. M., Apovian, C. M., & Boylan, M. O. (2023) · Obesity · doi:10.1002/oby.23758 · Cited by 9
“method, duodenal mucosal resurfacing [12], in which duodenal mucosa with the highest K-cell density [9] is ablated, has similarly shown marked improvements in hyperglycemia.”
MethodStrategies to Manage Obesity: Endoscopic Bariatric and Metabolic Therapies
Allencherril, R. P., & McCarty, T. R. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1518 · Cited by 8
Duodenal Laser Ablation for Treatment of Type 2 Diabetes: Results of First in Human Study
Kovarova, V., Laňková, I., Machytka, E., Knotkova, K., Kratochvílová, H., Beneš, M., Špičák, J., Vašura, A., Goldin, E., Munter, G., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.12762 · Cited by 9
“Although the exact mechanisms that underlie these therapies are as yet unclear and not fully defined, these findings do underscore the potential role of the duodenum as a bona fide target for the treatment of metabolic conditions including T2DM [18–20].”
Norton, B. C., Papaefthymiou, A., Telese, A., Neiponice, A., Hoebel, P. B., Vignolo, P., Grunert, L. R., & Haidry, R. J. (2025) · iGIE · doi:10.1016/j.igie.2025.03.008 · Cited by 8
“17 These SAEs were due to 3 cases of duodenal stenosis, which demonstrates the risk of excessive small intestinal ablation.”
Self-citationASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management
Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., Mergener, K., Dayyeh, B. A., Apovian, C. M., Burke, C. A., Chand, B., Chandraker, A. K., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.08.004 · Cited by 9
“Additionally, modest weight effects have been shown.(63) The device is under investigation in European trials.”
BackgroundSelf-citationFrom Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes
Guimarães, M., Pereira, S. S., & Monteiro, M. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_480 · Cited by 9
Boškoski, I., Matteo, M. V., Shamah, S., Dayyeh, B. K. A., Bove, V., Siena, M. D., Huberty, V., Maselli, R., Perretta, S., Pontecorvi, V., et al. (2025) · Endoscopy · doi:10.1055/a-2630-2062 · Cited by 10
“The most serious AE was duodenal stricture, which was successfully treated with a single dilation session [46].”
Jirapinyo, P., & Thompson, C. C. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07393-z · Cited by 7
Self-citationBariatric endoscopy: from managing complications to primary metabolic procedures
Dang, J. T., Kim, G. J., & Kroh, M. (2023) · Daehan nae'si'gyeong bog'gang'gyeong oe'gwa haghoeji/Journal of minimally invasive surgery · doi:10.7602/jmis.2023.26.1.1 · Cited by 7
“’s study [27] revealed a statistically significant reduction in HbA1c of 1.”
BackgroundMetabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
Norton, B. C., Papaefthymiou, A., Telese, A., Mallik, R., Murino, A., Johnson, G., Murray, C. D., Makaronidis, J., & Haidry, R. J. (2024) · Gastrointestinal Disorders · doi:10.3390/gidisord6010013 · Cited by 7
“…patients with T2D showed a clinically significant reduction in HbA1c following a single procedure with the Revita TM system (Fractyl Laboratories Inc., Lexington, MA, USA), although it was associated with three cases of duodenal stenosis that were successfully treated with balloon dilatation [28].”
MethodUpdate on Endoscopic Treatments for Obesity
PESSORRUSSO, F. C. S., Mehta, S. V., & Sullivan, S. A. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00551-6 · Cited by 9
“A first-in-human study demonstrated a clinically significant improvement in A1c of 1.2% at 6 months in patients with type 2 diabetes, with acceptable safety and tolerability [80].”
InfluentialMeiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01628-z · Cited by 7
“Duodenal Mucosal Resurfacing (DMR) is a minimally invasive endoscopic procedure that ablates the duodenal mucosa with subsequent regeneration [12].”
BackgroundMethodPhysiology Reconfigured: How Does Bariatric Surgery Lead to Diabetes Remission?
Albaugh, V. L., Axelrod, C. L., Belmont, K. P., & Kirwan, J. P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.06.003 · Cited by 9
Metadata
- Authors
- Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P.
- Affiliations
- Fractyl (United States) (US)
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- King's College London (GB)
- Catholic University of Rome, Rome, Italy
- CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
- Gastro Obeso Center, São Paulo, Brazil
- Corresponding author
- Rajagopalan, Harith
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-12
- Volume
- 39
- Issue
- 12
- Pages
- 2254-2261
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514895276
- Cited by
- 216
- References
- 35
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 17 · 2023: 14 · 2022: 17 · 2021: 25 · 2020: 34 · 2019: 24 · 2018: 20 · 2017: 32 · 2016: 2
- FWCI
- 26.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Fractyl Laboratories, Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- duodenal mucosal resurfacing, type 2 diabetes, HbA1c reduction, glycemic control, balloon catheter, duodenal stenosis, antidiabetic medication reduction, procedural safety, first-in-human study
- MeSH terms
- Adult, Aged, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Pilot Projects, Endoscopy, Gastrointestinal, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.